This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
diabetic-retinopathy
Diabetic Retinopathy
Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults; hyperglycemia → pericyte loss → microaneurysms → neovascularization (PDR) → vitreous hemorrhage. VEGF + Ang-2 drive macular edema; anti-VEGF and faricimab are the treatment standard.
Entry Metadata
| Field | Value |
|---|---|
| ID | diabetic-retinopathy |
| Name | Diabetic Retinopathy |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540-2553. · PubMed 15451934
- Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015;372(13):1193-1203. · PubMed 25692915
- Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE). Lancet. 2022;399(10326):741-755. · PubMed 35085503